Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Salgia

Showing results (41-50 of 528) with videos related to

Pageof 53
Sort By:
American Journal of Clinical Oncology|August 13, 2013
Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung CancerRobert M Sargis, Ravi Salgia
Cancer Biology & Therapy|February 12, 2010
The role of chemokine receptor CXCR4 in lung cancerTara Gangadhar, Suvobroto Nandi, Ravi Salgia
American Journal of Respiratory and Critical Care Medicine|November 17, 2012
CD14(+)S100A9(+) myeloid-derived suppressor cells portend decreased survival in patients with advanced lung cancerSherven Sharma, Steven Dubinett, Ravi Salgia
Cancer Biology & Therapy|January 17, 2007
A review of topoisomerase inhibition in lung cancerHatim Chhatriwala, Nazia Jafri, Ravi Salgia
Journal of Experimental Therapeutics & Oncology|December 18, 2003
Small cell lung cancer: from molecular biology to novel therapeuticsEvan Pisick, Simha Jagadeesh, Ravi Salgia
Methods in Molecular Medicine|April 25, 2003
Cell motility, adhesion, homing, and migration assays in the studies of tyrosine kinasesMartin Sattler, Elizabeth Quackenbush, Ravi Salgia
Methods in Molecular Medicine|November 6, 2002
Role of receptor tyrosine kinases in lung cancerGautam Maulik, Takashi Kijima, Ravi Salgia
Methods in Molecular Medicine|November 1, 2002
Molecular alterations in lung cancer. Impact on prognosisTakashi Kijima, Gautam Maulik, Ravi Salgia
JAMA Oncology|July 22, 2016
KRAS in Non-Small-Cell Lung Cancer-ReplyKevin Wood, Thomas Hensing, Ravi Salgia
Current Molecular Medicine|February 22, 2007
Tyrosine kinase mutations in human cancerErnst Lengyel, Kenjiro Sawada, Ravi Salgia
Pageof 53

Showing results (41-50 of 528) with videos related to

Sort By:
Pageof 53
American Journal of Clinical Oncology|August 13, 2013
Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung CancerRobert M Sargis, Ravi Salgia
Cancer Biology & Therapy|February 12, 2010
The role of chemokine receptor CXCR4 in lung cancerTara Gangadhar, Suvobroto Nandi, Ravi Salgia
American Journal of Respiratory and Critical Care Medicine|November 17, 2012
CD14(+)S100A9(+) myeloid-derived suppressor cells portend decreased survival in patients with advanced lung cancerSherven Sharma, Steven Dubinett, Ravi Salgia
Cancer Biology & Therapy|January 17, 2007
A review of topoisomerase inhibition in lung cancerHatim Chhatriwala, Nazia Jafri, Ravi Salgia
Journal of Experimental Therapeutics & Oncology|December 18, 2003
Small cell lung cancer: from molecular biology to novel therapeuticsEvan Pisick, Simha Jagadeesh, Ravi Salgia
Methods in Molecular Medicine|April 25, 2003
Cell motility, adhesion, homing, and migration assays in the studies of tyrosine kinasesMartin Sattler, Elizabeth Quackenbush, Ravi Salgia
Methods in Molecular Medicine|November 6, 2002
Role of receptor tyrosine kinases in lung cancerGautam Maulik, Takashi Kijima, Ravi Salgia
Methods in Molecular Medicine|November 1, 2002
Molecular alterations in lung cancer. Impact on prognosisTakashi Kijima, Gautam Maulik, Ravi Salgia
JAMA Oncology|July 22, 2016
KRAS in Non-Small-Cell Lung Cancer-ReplyKevin Wood, Thomas Hensing, Ravi Salgia
Current Molecular Medicine|February 22, 2007
Tyrosine kinase mutations in human cancerErnst Lengyel, Kenjiro Sawada, Ravi Salgia
Pageof 53